San Jose, California-based Procept designed Hydros to treat benign prostatic hyperplasia (BPH). The company says it represents the first AI-enabled robotic platform designed specifically for the treatment of BPH.
Aquablation uses waterjet resection to precisely eradicate prostate tissue. It provides the potential for an effective cancer treatment while maintaining the patient’s quality of life.
“Many men living with BPH remain on long-term medication or delay surgery because they are concerned about potential trade-offs between symptom relief and side effects,” said Larry Wood, President & CEO, Procept BioRobotics. “The HYDROS Robotic System expands international access to a clinically validated, next-generation AI-enabled robotic solution that delivers durable symptom relief while preserving quality of life. We are proud to bring this innovation to physicians and patients across the UK and to continue expanding our international footprint.”
More about the Procept BioRobotics Hydros system
Hydros received FDA clearance for treating BPH in August 2024. The platform leverages AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility.
The system’s real-time imaging provides a multi-dimensional view of the prostate. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once mapped, the robotic-assisted execution enables prostate tissue removal in a precise, targeted and controlled manner.
Procept designed its platform to support scalable adoption across care settings while maintaining consistent procedural execution.
The milestone for Procept Biorobotics comes as a handful of other BPH treatment options make waves. ProVerum and Zenflow announced FDA approvals for their implant-based technologies that treat BPH in December 2025. In January of this year, Butterfly Medical said it completed the final 12-month follow-up for all patients in a study of its prostatic retraction device for BPH.
